Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (151-160 of 260) with videos related to

Pageof 26
Sort By:
NPJ Precision Oncology|July 7, 2025
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanomaNatalie Y L Ngoi, Ian M Silverman, Adrienne Johnson, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Journal of Hematology|July 15, 2022
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series ExperienceBlessie Elizabeth Nelson, Chinenye Lynette Ejezie, Bettzy A Stephen, et al.
British Journal of Cancer|November 1, 2018
Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinomaNada M S Al-Saffar, Helen Troy, Anne-Christine Wong Te Fong, et al.
Cancer|June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumorsTimothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Pageof 26

Showing results (151-160 of 260) with videos related to

Sort By:
Pageof 26
NPJ Precision Oncology|July 7, 2025
Exceptional response to the ATR inhibitor, camonsertib, in a patient with ALT+ metastatic melanomaNatalie Y L Ngoi, Ian M Silverman, Adrienne Johnson, et al.
British Journal of Cancer|May 17, 2025
The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa studyTimothy A Yap, Patricia LoRusso, Rowan E Miller, et al.
Journal of Hematology|July 15, 2022
Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series ExperienceBlessie Elizabeth Nelson, Chinenye Lynette Ejezie, Bettzy A Stephen, et al.
British Journal of Cancer|November 1, 2018
Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinomaNada M S Al-Saffar, Helen Troy, Anne-Christine Wong Te Fong, et al.
Cancer|June 19, 2025
First-in-human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumorsTimothy A Yap, Olivier Rixe, Capucine Baldini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2025
Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast CancerMohamed A Gouda, Amrit Gonugunta, Ecaterina E Dumbrava, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 23, 2008
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone drivenGerhardt Attard, Alison H M Reid, Timothy A Yap, et al.
The New England Journal of Medicine|June 26, 2009
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriersPeter C Fong, David S Boss, Timothy A Yap, et al.
Molecular Cancer Therapeutics|April 29, 2025
Efficacy of ATR kinase inhibitor elimusertib monotherapy or combination in tumors with DNA damage response pathway and other genomic alterationsKaushik Varadarajan, Christian X Cruz Pico, Kurt W Evans, et al.
Clinical and Translational Science|February 10, 2026
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid TumorsJatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, et al.
Pageof 26